Serial No.: 09/937,162 Filed: March 7, 2002

Page : 2 of 12

/

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-5. (cancelled)

6. (currently amended) A method of identifying an agent-having cellular antiproliferation activity that activates TSA-responsive Sp3-mediated transcription, the method comprising:

providing a cell having (a) a first vector comprising a first regulatory sequence operably linked to a nucleic acid sequence encoding a fusion protein, wherein the fusion protein comprises (i) a fragment of Sp3-or a fragment thereof (1) having transcriptional activation activity, (2) comprising at least one glutamine rich region of a TSA responsive domain of Sp3, and (3) lacking at least part of the zinc finger region of Sp3, and (ii) a DNA binding domain of a heterologous protein; and (b) a second vector comprising a target binding sequence for the DNA binding domain of the fusion protein operably linked to a reporter gene;

contacting the cell with a test agent; and

selecting a test agent that increases the expression of the reporter gene compared to a control.

- 7. (Previously presented) The method of claim 6, wherein the heterologous protein is not endogenous to the cell.
- 8. (Previously presented) The method of claim 7, wherein the heterologous protein is GAL4, LexA or tetracycline repressor.

Serial No.: 09/937,162 Filed: March 7, 2002

Page : 3 of 12

9. (Previously presented) The method of claim 6, wherein the reporter gene encodes luciferase, chloramphenicol acetyltransferase, beta-galactosidase, human growth hormone or secreted alkaline phosphatase.

- 10. (Previously presented) The method of claim 8, wherein the reporter gene encodes luciferase, chloramphenicol acetyltransferase, beta-galactosidase, human growth hormone or secreted alkaline phosphatase.
- 11. (Previously presented) The method of claim 6, wherein the fusion protein comprises at least one glutamine-rich region of Sp3.
- 12. (Previously presented) The method of claim 8, wherein the fusion protein comprises at least one glutamine-rich region of Sp3.
- 13. (Previously presented) The method of claim 9, wherein the fusion protein comprises at least one glutamine-rich region of Sp3.
- 14. (Previously presented) The method of claim 6, wherein the second vector comprises a second regulatory sequence operably linked to the reporter gene.
- 15. (Previously presented) The method of claim 8, wherein the second vector comprises a second regulatory sequence operably linked to the reporter gene.
- 16. (Previously presented) The method of claim 9, wherein the second vector comprises a second regulatory sequence operably linked to the reporter gene.
- 17. (Previously presented) The method of claim 6, wherein the test agent is a low molecular weight compound.

Serial No.: 09/937,162 Filed: March 7, 2002

Page : 4 of 12

18. (Withdrawn) The method of claim 6, further comprising evaluating the selected test agent for anti-cancer activity.

19. (Withdrawn)

The method of claim 18, wherein the test agent is evaluated for anti-cancer activity *in vitro*.

- 20. (Withdrawn) The method of claim 18, wherein the test agent is evaluated for anti-cancer activity *in vivo*.
- 21. (Withdrawn) An anticancer agent comprising a compound that increases the transcriptional activity mediated by Sp3 and a pharmaceutical carrier, wherein the anticancer agent is not TSA, trapoxin, or sodium butyrate.
- 22. (Withdrawn) An anticancer agent identified by the method of claim 6, wherein the anticancer agent is not TSA, trapoxin, or sodium butyrate.
- 23. (Withdrawn) An anticancer agent identified by the method of claim 8, wherein the anticancer agent is not TSA, trapoxin, or sodium butyrate.
- 24. (Withdrawn) An anticancer agent identified by the method of claim 9, wherein the anticancer agent is not TSA, trapoxin, or sodium butyrate.
- 25. (New) The method of claim 6, further comprising evaluating the selected test agent for cellular anti-proliferative activity.

Serial No.: 09/937,162 Filed: March 7, 2002

Page : 5 of 12

26. (New) The method of claim 6, further comprising identifying the selected test agent as having potential cellular anti-proliferative activity.

- 27. (New) The method of claim 6, wherein the Sp3 is human Sp3.
- 28. (New) The method of claim 6, wherein the fusion protein comprises at least one of the two glutamine-rich regions comprising amino acids 10-123 or 223-358 of human Sp3.
- 29. (New) The method of claim 6, wherein the fusion protein lacks at least part of a Zinc finger region selected from the group consisting of amino acids 495-517, 525-547, and 555-575 of human Sp3.